Randomized placebo controlled human pharmacology study· 2026
Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans
Galbiati F; Plessow F; Plummer L; Campbell MB; Nazarloo S; Carter CS
Journal of neuroendocrinology
- PubMed
- 41273106
- Evidence level
- moderate
- Verification
- verified
Summary
Secondary pharmacodynamic analysis of the same NCT00914823 cohort: IV kisspeptin did NOT change serum vasopressin. A negative pharmacology finding, useful for boundary-of-action claims.
Limitations
Cohort overlaps entirely with PMID 39965102 — same NCT00914823 subjects; cannot be counted as an independent trial; small n=12; single-dose bolus only; assay-limited detection sensitivity for AVP.